Loading...
Docoh

Acer Therapeutics (ACER)

News

From Benzinga Pro
12 Health Care Stocks Moving In Tuesday's Pre-Market Session
17 May 22
Pre-Market Outlook, Markets, Movers
24 Stocks Moving in Tuesday's Pre-Market Session
17 May 22
News, Penny Stocks, Small Cap, Pre-Market Outlook, Markets, Movers, Trading Ideas
Gainers Bird Global, Inc. (NASDAQ: BRDS) rose 26.3% to $1.24 in pre-market trading after the company posted strong Q1 sales.
12 Health Care Stocks Moving In Monday's After-Market Session
16 May 22
Movers
Gainers Adaptimmune Therapeutics (NASDAQ:ADAP) stock rose 12.7% to $1.6 during Monday's after-market session. The market value of their outstanding shares is at $258.9 million.
Acer Therapeutics: Q1 Earnings Insights
16 May 22
Earnings
Acer Therapeutics (NASDAQ:ACER) reported its Q1 earnings results on Monday, May 16, 2022 at 04:01 PM. Here's what investors need to know about the announcement.
Acer Therapeutics Q1 EPS $(0.64) Down From $(0.33) YoY
16 May 22
Earnings, News
Acer Therapeutics (NASDAQ:ACER) reported quarterly losses of $(0.64) per share. This is a 93.94 percent decrease over losses of $(0.33) per share from the same period last year.
Acer Therapeutics Announces Agreement With FDA On Special Protocol Assessment For Its Phase 3 EDSIVO Trial In Vascular Ehlers-Danlos Syndrome Patients
9 May 22
Biotech, News, FDA, General
Phase 3 DiSCOVER clinical trial initiation expected by end of Q2 2022 NEWTON, Mass., May 09, 2022 (GLOBE NEWSWIRE) -- Acer Therapeutics Inc. (NASDAQ:ACER), a pharmaceutical company focused on the acquisition,
12 Health Care Stocks Moving In Tuesday's Pre-Market Session
5 Apr 22
Pre-Market Outlook, Markets, Movers
12 Health Care Stocks Moving In Monday's Pre-Market Session
4 Apr 22
Movers
Acer Therapeutics' EDSIVO (celiprolol) Granted FDA Breakthrough Therapy Designation For Vascular Ehlers-Danlos Syndrome
4 Apr 22
News, FDA
Acer Therapeutics Inc. (NASDAQ:ACER), a pharmaceutical company focused on the acquisition, development and commercialization of therapies for serious rare and life-threatening diseases with significant unmet medical
Acer Therapeutics Reports Enrollment Of First Patient In Its Phase 2a Trial Of ACER-801 For Treatment Of Moderate To Severe Vasomotor Symptoms Associated With Menopause
30 Mar 22
Biotech, News, FDA, General
Acer Therapeutics Inc. (NASDAQ:ACER), a pharmaceutical company focused on the acquisition, development and commercialization of therapies for serious rare and life-threatening diseases with significant unmet medical
12 Health Care Stocks Moving In Tuesday's Pre-Market Session
8 Mar 22
Pre-Market Outlook, Markets, Movers
Acer Therapeutics Q4 EPS $(0.31) Up From $(0.50) YoY
2 Mar 22
Earnings, News
Acer Therapeutics (NASDAQ:ACER) reported quarterly losses of $(0.31) per share. This is a 38 percent increase over losses of $(0.50) per share from the same period last year.

Press releases

From Benzinga Pro
Acer Therapeutics Reports Q1 2022 Financial Results and Provides Corporate Update
16 May 22
Earnings, Press Releases
NEWTON, Mass., May 16, 2022 (GLOBE NEWSWIRE) -- Acer Therapeutics Inc. (NASDAQ:ACER), a pharmaceutical company focused on the acquisition, development and commercialization of therapies for serious, rare and
Acer Therapeutics Announces Agreement with FDA on Special Protocol Assessment for its Phase 3 EDSIVO™ (celiprolol) Trial in Vascular Ehlers-Danlos Syndrome Patients
9 May 22
Health Care, Press Releases
NEWTON, Mass., May 09, 2022 (GLOBE NEWSWIRE) -- Acer Therapeutics Inc. (NASDAQ:ACER), a pharmaceutical company focused on the acquisition, development and commercialization of therapies for serious rare and
Acer Therapeutics and Relief Therapeutics Announce Presentation of ACER-001 Data at the Genetic Metabolic Dieticians International Conference
6 May 22
Health Care, Press Releases
NEWTON, Mass. and GENEVA, May 06, 2022 (GLOBE NEWSWIRE) -- Acer Therapeutics Inc. (NASDAQ:ACER) ("Acer") and its collaboration partner, Relief Therapeutics Holding SA ((SIX: RLF, OTCQB:RLFTF, RLFTY)) ("Relief"), today
Acer Therapeutics and Relief Therapeutics Announce Presentation of ACER-001 Data at the Genetic Metabolic Dieticians International Conference
6 May 22
News, Press Releases
NEWTON, MA and GENEVA, SWITZERLAND / ACCESSWIRE / May 6, 2022 / Acer Therapeutics Inc. (NASDAQ:ACER) ("Acer") and its collaboration partner, Relief Therapeutics Holding SA ((SIX:RLF, OTCQB:RLFTF, RLFTY))
Acer Therapeutics to Participate in H.C. Wainwright Global Investment Conference
5 May 22
News, Press Releases
NEWTON, Mass., May 05, 2022 (GLOBE NEWSWIRE) -- Acer Therapeutics Inc. (NASDAQ:ACER), a pharmaceutical company focused on the acquisition, development and commercialization of therapies for serious rare and
Acer Therapeutics and Relief Therapeutics Announce Presentation of ACER-001 Data at the Society for Inherited Metabolic Disorders Annual Meeting
12 Apr 22
Contracts, Press Releases
NEWTON, MA and GENEVA, SWITZERLAND / ACCESSWIRE / April 12, 2022 / Acer Therapeutics Inc. (NASDAQ:ACER) ("Acer") and its collaboration partner, Relief Therapeutics Holding SA (SIX:RLF)(OTCQB:RLFTF)(OTCQB:RLFTY)
SWK Holdings Corporation Announces Financial Results for Fourth Quarter and Full-Year 2021
28 Mar 22
Earnings, Press Releases
Conference Call and Live Audio Webcast Scheduled for Monday, March 28, 2022, at 10:00 a.m. ET Corporate Highlights Reconstituted Board and appointed Wendy DiCicco, Robert K. Hatcher, and Laurie Dotter as independent
Acer Therapeutics Secures up to $48.5 Million in Convertible Note and Secured Loan Financing Facilities
7 Mar 22
Markets, Press Releases
NEWTON, Mass., March 07, 2022 (GLOBE NEWSWIRE) -- Acer Therapeutics Inc. (NASDAQ:ACER), a pharmaceutical company focused on the acquisition, development and commercialization of therapies for serious rare and
Acer Therapeutics Reports Q4 and Full Year 2021 Financial Results and Provides Corporate Update
2 Mar 22
Earnings, Press Releases
NEWTON, Mass., March 02, 2022 (GLOBE NEWSWIRE) -- Acer Therapeutics Inc. (NASDAQ:ACER), a pharmaceutical company focused on the acquisition, development and commercialization of therapies for serious, rare and